



M Castiglione-Gertsch

Kontakt

M Castiglione-Gertsch

Publikationen (25)

Karlsson P, Gruber G, Goldhirsch A, Gelber R, Forbes J, Castiglione-Gertsch M, Crivellari D, Thürlimann B, Kovács A, Collins J, Lindtner J, Price K, Chua B, Cole B, International Breast Cancer Study Group. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. *Ann Oncol* 2012; 23:2852-8.

Rabaglio M, Coates A, Goldhirsch A, Gelber R, Smith I, Láng I, Nogaret J, Pienkowski T, Colleoni M, Paridaens R, Forbes J, Campone M, Mouridsen H, Thürlimann B, Hawle H, Castiglione-Gertsch M, Price K, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. *Ann Oncol* 2009; 20:1489-98.

Viale G, Goldhirsch A, Gelber R, Öhlschlegel C, Karlsson P, Crivellari D, Golouh R, Brown R, Price K, Regan M, Castiglione-Gertsch M, Colleoni M, Mallon E, Sonzogni A, Mastropasqua M, Maiorano E, Gusterson B, Giobbie-Hurder A, Coates A. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. *Ann Oncol* 2009; 21:245-54.

Gruber G, Gusterson B, Viale G, Goldhirsch A, Price K, Coates A, Gelber R, Fey M, Simoncini E, Thürlimann B, Crivellari D, Collins J, Golouh R, Lindtner J, Holmberg S, Castiglione-Gertsch M, Cole B, International Breast Cancer Study Group. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. *Ann Oncol* 2008; 19:1393-401.

Regan M, SOFT/TEXT/PERCHE Steering Committee, Gelber R, Goldhirsch A, Coates A, Castiglione-Gertsch M, Maibach R, Thürlimann B, Price K, Fleming G, Francis P, Perez E, Torrisi R, Walley B, Pagani O, International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. *Ann Oncol* 2008; 19:1231-41.

Bernhard J, Coates A, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Colleoni M, Green M, Thürlimann B, Yeo W, Aebi S, Forbes J, Hürny C, Basser R, Martinelli G, Zhang J, Zahrieh D, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWIST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. *BJC* 2008; 98:25-33.

Mauriac L, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R, Nogaret J, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. *Ann Oncol* 2007; 18:859-67.

Colleoni M, Veronesi A, Holmberg S, Erzen D, Forbes J, Murray E, Thürlimann B, Simoncini E, Pagani O, Collins J, Crivellari D, Rudenstam C, Lindtner J, Price K, Castiglione-Gertsch M, Coates A, Gelber R, Li S, Goldhirsch A. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. *Ann Oncol* 2005; 16:716-25.

Hess D, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann B, Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2004; 15:1760-5.

Bernhard J, Goldhirsch A, Price K, Fey M, Thürlimann B, Veronesi A, Crivellari D, Rudenstam C, Snyder R, Collins J, Perey L, Forbes J, Murray E, Castiglione-Gertsch M, Gelber R, Coates A, Zahrieh D, Hürny C. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. *BJC* 2004; 91:1893-901.

Berclaz G, Thürlimann B, Fey M, Mendiola C, Werner I, Simoncini E, Crivellari D, Gelber R, Goldhirsch A, Snyder R, Collins J, Li S, Price K, Coates A, Castiglione-Gertsch M, Rudenstam C, Holmberg S, Lindtner J, Erien D, International Breast Cancer Study Group. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. *Ann Oncol* 2004; 15:875-84.

Fogliata A, Schefer H, Curti G, Schott A, Zenklusen H, Roth A, Morel P, Gertsch P, Gervaz P, Davis J, Székely G, Burger C, Huser M, Kolotas C, Thalmann G, Guillou L, Jichlinski P, von Briel C, Beer K, Miralbell R, Escudé L, Mollà M, Nouet P, Rouzaud M, Mini R, Kemmerling L, Vetterli D, Lütolf U, Ulmer U, Oehler C, Weber D, Bolsi A, Lomax A, Timmermann B, Goitein G, Verwey J, Pedroni E, Rutz H, Lomax A, Weber D, Luthi F, Pasche P, Bentzen S, Khalil A, Dubois J, Pica A, Stupp R, Stadelmann O, Allaoua M, Kebdani T, Slosman D, Dische S, Cummings B, Van den Bogaert W, Horiot J, Saunders M, Isaak B, Pesce G, Popowski Y, Tebeu P, Matzinger O, Betz M, Corminboeuf F, Bouville S, Özsoy O, Bigler R, Veas H, Girardet C, Abdou M, Huguenin P, Verkooijen H, Bouchardy C, Franzetti A, Richetti A, Presilla S, Motta M, Valley J, Bressan S, Bulling S, Pache G, Merçay A, Major A, Usel M, Ludicke F, Rufibach K, Ries G, Coucke P, Wang H, Pasche G, Do H, Balmer A, Munier F, Jargy C, Dipasquale G, Born E, Szczerba D, Hueber P, Hafner H, Cozzi L, Moeckli R, Boehringer T, Collen T, Luluhová D, Allemann K, Bründler M, Krayenbühl J, Schoenmaker E, Norton I, Baumert B, Rutz H, Pedroni E, Lin S, Coray A, Nicolini G, Veas H, Martineau P, Gourgou S, Zouhair A, Ozsahin M, Cunat S, Larbouret C, Azria A, Bonny C, Hofstetter B, Tenzer A, Krek W, Lutters G, Evans D, Romieu G, Bodis S, Stahel R, Weder W, Jerman M, Schneiter D, Jörgler M, Lardinois D, Taverna C, Kestenholz P, Heuberger J, Pèlegri A, Pujol P, Zimmer Y, Greiner R, Gruber G, Ametamey S, Bodis S, Zingg D, Jochum W, Vuong V, Honer M, Riesterer O, Mhawech P, Verdán C, Tschanz E, Dulguerov P, Ares C, Pruschy M, Inteeworn N, Stalder D, Streit B, Ganapathipillai S, Aebbersold D, Berthou S, Kaser-Hotz B, Gassmann M, Rohrer Bley C, Wergin M, Roos M, Höpfl G, Ohlerth S, Allal A, Behrensmeier F, Thürlimann B, Carbone A, Crivellari D, Collins J, Gol-Ouh R, Lindtner J, Holmberg S, Rudenstam C, Castiglione-Gertsch M, Price K, Nasi M, Bonetti M, Simoncini E, Fey M, Bortoluzzi L, Weitzel M, Kranzbuehler H, Becker M, Taussky D, Azria D, Mirimanoff R, Kramar A, Jeanneret Sozzi W, Goldhirsch A, Coates A, Gelber R, Ueltschi G, Lippold B, Kranzbühler H, Bernier J, Studer G, Landmann C, Mahler F, Greiner R, Taverna C, Stanek N, Ciernik I, Friedrich E, Beer K, Balmer Majno S, Hügli A, Gallino A, Juelke P, Pajic B, Curschmann J, Bieri S, Luthi J, Suleiman M, Bargetzi M, Notter M, Thum P, Resink T, Erne P, Jamshidi P, Hafner H, Mach N. Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO). *Strahlenther Onkol* 2004; 180 Suppl 1:89-108.

Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner K, Borner M, Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2003; 14:1215-21.

Wallgren A, Collins J, Coates A, Price K, Forbes J, Werner I, Fey M, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Goldhirsch A, Gelber R, Bonetti M, International Breast Cancer Study Group Trials I through VII. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2003; 21:1205-13.

Colleoni M, Collins J, Thürlimann B, Holmberg S, Crivellari D, Beyerle C, Neumann R, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C, Litman H, Castiglione-Gertsch M, Sauerbrei W, Gelber R, Bonetti M, Coates A, Schumacher M, Bastert G, German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. *British journal of cancer* 2002; 86:1705-14.

Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Gelber S, International Breast Cancer Study Group. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2001; 19:4141-9.

Colleoni M, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R, Bonetti M, Thürlimann B, Price K, Castiglione-Gertsch M, Coates A, Rudenstam C. Identifying breast cancer patients at high risk for bone metastases. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18:3925-35.

Aebi S, Coates A, Werner I, Simoncini E, Cortes-Funes H, Crivellari D, Lindtner J, Rudenstam C, Thürlimann B, Collins J, Gelber R, Castiglione-Gertsch M, Gelber S, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. *Lancet* 2000; 355:1869-74.

Crivellari D, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, Bernhard J, Bonetti M, Castiglione-Gertsch M, Gelber R, Rudenstam C, Thürlimann B, Price K, Coates A, Hürny C, Goldhirsch A. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18:1412-22.

Colleoni M, Marini G, Veronesi A, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Bonetti M, Goldhirsch A. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18:584-90.

Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S, Thürlimann B, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 1999; 17:1672-9.

Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Thürlimann B, Schmitz S, Castiglione-Gertsch M, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). *European journal of cancer (Oxford, England : 1990)* 1999; 35:913-20.

Colleoni M, Thürlimann B, Gelber R, Collins J, Lindtner J, Coates A, Goldhirsch A, Castiglione-Gertsch M, Price K, Rudenstam C. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. *European journal of cancer (Oxford, England : 1990)* 1998; 34:1693-700.

Bernhard J, Senn H, Goldhirsch A, Forbes J, Thürlimann B, Marini G, Galligioni E, Gelber R, Castiglione-Gertsch M, Peterson H, Coates A, Hürny C, Rudenstam C. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). *British journal of cancer* 1998; 78:686-93.

Thürlimann B, Fey M, Senn H, Cavalli F, Jungi W, Goldhirsch A, Castiglione-Gertsch M, Bacchi M, Beretta K, Löhnert T. First-line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 1996; 7:471-9.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch